![]() |
![]() |
My Amedeo
![]() ![]() ![]() |
![]() |
|||||||||
Stroke prevention |
Malignant Lymphoma |
Free Subscription
1 Am J Hematol |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Malignant Lymphoma is free of charge.
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes
treatment resistance in R/R NHL: Results from preclinical models and a Phase Ib
study.
Am J Hematol. 2023 Jan 2. doi: 10.1002/ajh.26809.
PubMed
Abstract available
Effusion presentation of HHV-8-associated multicentric Castleman disease
mimicking primary effusion lymphoma.
Blood. 2023;141:320.
PubMed
TOXic T-cell cytokines wreak havoc in CTCL skin.
Blood. 2023;141:127-128.
PubMed
Staging lymph nodes and blood at diagnosis in mycosis fungoides identifies
patients at increased risk of progression to advanced stage: A retrospective
cohort study.
Cancer. 2023;129:541-550.
PubMed
Abstract available
A phase 1 study to evaluate the safety, pharmacology, and feasibility of
continuous infusion nelarabine in patients with relapsed and/or refractory
lymphoid malignancies.
Cancer. 2023;129:580-589.
PubMed
Abstract available
High risk of infection in 'real-world' patients receiving ibrutinib, idelalisib
or venetoclax for mature B-cell leukaemia/lymphoma.
Eur J Haematol. 2023 Jan 19. doi: 10.1111/ejh.13928.
PubMed
Abstract available
Global reported impacts of COVID-19 on lymphoma patients and the emerging
clinical management approaches in response to the ongoing pandemic.
Eur J Haematol. 2023 Jan 19. doi: 10.1111/ejh.13926.
PubMed
Abstract available
Outcomes of coronavirus disease 2019 (COVID-19) and risk factors associated with
severe COVID-19 in patients with mature B-cell non-Hodgkin lymphomas: A US
electronic health record cohort study.
Eur J Haematol. 2023;110:177-187.
PubMed
Abstract available
The role of additional chemotherapy prior to autologous HCT in patients with
relapse/refractory DLBCL in partial remission-A retrospective multicenter study.
Eur J Haematol. 2023;110:149-156.
PubMed
Abstract available
Treatment patterns and real-world effectiveness of rituximab maintenance in older
patients with mantle cell lymphoma: a population-based analysis.
Haematologica. 2023 Jan 19. doi: 10.3324/haematol.2022.282252.
PubMed
Abstract available
Circulating Tumor DNA in the Blood: A New Frontier in Primary CNS Lymphoma?
J Clin Oncol. 2023 Jan 20:JCO2202605. doi: 10.1200/JCO.22.02605.
PubMed
Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning
regimen for autologous stem cell transplantation in lymphoma.
Leuk Lymphoma. 2023 Jan 19:1-8. doi: 10.1080/10428194.2023.2167492.
PubMed
Abstract available
Outcomes of allogeneic hematopoietic stem cell transplantation in secondary
central nervous system lymphoma: a case series.
Leuk Lymphoma. 2023 Jan 17:1-4. doi: 10.1080/10428194.2022.2151839.
PubMed
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and
refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label
phase II study.
Leuk Lymphoma. 2023 Jan 15:1-4. doi: 10.1080/10428194.2022.2164194.
PubMed
Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation
in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study.
Leukemia. 2023 Jan 18. doi: 10.1038/s41375-022-01780.
PubMed
Abstract available
Promoting effects of calponin 3 on the growth of diffuse large B‑cell lymphoma
cells.
Oncol Rep. 2023;49:46.
PubMed
Abstract available
Thank you for your interest in scientific medicine.
This policy is made possible thanks to
a media sponsorship by